AIC100
Anaplastic & Advanced Differentiated Thyroid Cancer
Key Facts
About AffyImmune Therapeutics
AffyImmune Therapeutics is pioneering a novel approach to CAR T therapy aimed at overcoming the key challenges in treating solid tumors, such as on-target/off-tumor toxicity and lack of persistence. Its differentiated platform centers on affinity tuning against the ICAM-1 target and enabling noninvasive patient monitoring. The company has achieved significant regulatory milestones, including FDA RMAT designation for its lead program in anaplastic thyroid cancer, positioning it in the vanguard of solid tumor cell therapy development.
View full company profileAbout AffyImmune Therapeutics
AffyImmune Therapeutics is pioneering a novel approach to CAR T therapy aimed at overcoming the key challenges in treating solid tumors, such as on-target/off-tumor toxicity and lack of persistence. Its differentiated platform centers on affinity tuning against the ICAM-1 target and enabling noninvasive patient monitoring. The company has achieved significant regulatory milestones, including FDA RMAT designation for its lead program in anaplastic thyroid cancer, positioning it in the vanguard of solid tumor cell therapy development.
View full company profile